SK21295A3 - Pharmaceutical composition for hiv-infection treatment - Google Patents

Pharmaceutical composition for hiv-infection treatment Download PDF

Info

Publication number
SK21295A3
SK21295A3 SK212-95A SK21295A SK21295A3 SK 21295 A3 SK21295 A3 SK 21295A3 SK 21295 A SK21295 A SK 21295A SK 21295 A3 SK21295 A3 SK 21295A3
Authority
SK
Slovakia
Prior art keywords
hiv
cells
pharmaceutical composition
treatment
pct
Prior art date
Application number
SK212-95A
Other languages
English (en)
Slovak (sk)
Inventor
Jerome Schwartz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of SK21295A3 publication Critical patent/SK21295A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
SK212-95A 1992-08-19 1993-08-17 Pharmaceutical composition for hiv-infection treatment SK21295A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93213492A 1992-08-19 1992-08-19
PCT/US1993/007587 WO1994004179A1 (en) 1992-08-19 1993-08-17 Method for inhibiting hiv replication using il-4

Publications (1)

Publication Number Publication Date
SK21295A3 true SK21295A3 (en) 1997-01-08

Family

ID=25461831

Family Applications (1)

Application Number Title Priority Date Filing Date
SK212-95A SK21295A3 (en) 1992-08-19 1993-08-17 Pharmaceutical composition for hiv-infection treatment

Country Status (22)

Country Link
US (1) US5700461A (no)
EP (1) EP0656785B1 (no)
JP (1) JP2711182B2 (no)
KR (1) KR950702838A (no)
CN (1) CN1086437A (no)
AT (1) ATE163860T1 (no)
AU (1) AU683427B2 (no)
CA (1) CA2142862C (no)
CZ (1) CZ38095A3 (no)
DE (1) DE69317428T2 (no)
ES (1) ES2113549T3 (no)
FI (1) FI950696A (no)
HU (1) HUT72709A (no)
IL (1) IL106717A0 (no)
MX (1) MX9305016A (no)
NO (1) NO950599L (no)
NZ (1) NZ255735A (no)
PL (1) PL307508A1 (no)
SK (1) SK21295A3 (no)
TW (1) TW291439B (no)
WO (1) WO1994004179A1 (no)
ZA (1) ZA936018B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0858343B1 (en) 1995-11-02 2004-03-31 Schering Corporation Continuous low-dose cytokine infusion therapy
US20040132161A1 (en) * 1998-04-20 2004-07-08 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20050124645A1 (en) * 1998-04-20 2005-06-09 Finkel Terri H. Methods and compositions for increasing CD4lymphocyte immune responsiveness
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
CA2335617C (en) * 1998-06-24 2009-12-15 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
JPH02485A (ja) * 1987-08-03 1990-01-05 Yuu Honshiyo 新規なヒトインターロイキン４、該因子を発現させるための組換えベクター及びそのベクターにより形質転換された形質転換体
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
CA2078676A1 (en) * 1990-03-21 1991-09-22 Jerome Schwartz Use of il-4 to enhance immune response to infectious antigenic challenges
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
EP0490006B1 (en) * 1990-12-13 1994-06-22 Schering-Plough Pharmaceutical compositions for the treatment of B-cell malignancies

Also Published As

Publication number Publication date
NZ255735A (en) 1997-06-24
KR950702838A (ko) 1995-08-23
ES2113549T3 (es) 1998-05-01
FI950696A0 (fi) 1995-02-16
HUT72709A (en) 1996-05-28
US5700461A (en) 1997-12-23
WO1994004179A1 (en) 1994-03-03
PL307508A1 (en) 1995-05-29
CZ38095A3 (en) 1995-12-13
IL106717A0 (en) 1993-12-08
NO950599D0 (no) 1995-02-17
JPH07506116A (ja) 1995-07-06
AU5007593A (en) 1994-03-15
HU9500487D0 (en) 1995-04-28
EP0656785B1 (en) 1998-03-11
CA2142862A1 (en) 1994-03-03
DE69317428D1 (de) 1998-04-16
EP0656785A1 (en) 1995-06-14
MX9305016A (es) 1994-02-28
CA2142862C (en) 2000-05-30
ZA936018B (en) 1994-06-13
TW291439B (no) 1996-11-21
CN1086437A (zh) 1994-05-11
FI950696A (fi) 1995-02-16
AU683427B2 (en) 1997-11-13
ATE163860T1 (de) 1998-03-15
JP2711182B2 (ja) 1998-02-10
NO950599L (no) 1995-02-17
DE69317428T2 (de) 1998-07-02

Similar Documents

Publication Publication Date Title
Mutter et al. Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host.
AU680858B2 (en) Therapeutic combination containing interferon
KR20160030099A (ko) 세포내 감염의 치료 방법
SK21295A3 (en) Pharmaceutical composition for hiv-infection treatment
Nunnari et al. IL-7 as a potential therapy for HIV-1-infected individuals
DK162923B (da) Farmaceutisk praeparat til inhibering af tumorcellevaekst og fremgangsmaade til fremstilling deraf
Webster Virus infections in primary immunodeficiency.
Domke-Opitz et al. Role of interferon in persistent infection of macrophages with herpes simplex virus
PT97082B (pt) Processo para a preparacao de uma composicao farmaceutica contendo il-4,util para aumentar a resposta imunitaria a agressoes de antigenios infecciosos
Prakash et al. The Human Innunodeficiency Virus Type I Tatt Protein Potentiates Ethanol‐Induced Neutrophil Functional Impairment in Transgenic Mice
Larsen et al. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects
Martı́n et al. Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients
Dandoy et al. Mouse genes influence antiviral action of interferon in vivo
CN112569250A (zh) 三氟尿苷制备hiv-1药物中的应用
Kohl et al. Defective production of antibody to herpes simplex virus in neonates: defective production of T helper lymphokine and induction of suppression
Macchi et al. Mononuclear cells from peripheral blood of adult donors and from cord blood are equally protected by α-and β-interferons against infection with HTLV-I
Upadhyay et al. The effect of HSV multiplication rate on antiviral drug efficacy in vitro
US7968298B2 (en) Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit CCR5-tropic HIV-1 infection and replication
Aul et al. Interferons: Biological Activities and Clinical Efficacy
CN114246874A (zh) 鲁斯可皂苷元在预防冠状病毒感染中的应用
US20110159020A1 (en) Transcription Factor for Killer Cell Activation, Differentiation and Uses Thereof
Zhang et al. Infusion of leukocytes from HLA haplo-identical familial donors as an adjuvant in the HLH-2004 protocol to treat the virus-associated adult hemophagocytic lymphohistiocytosis: a retrospective study of 26 patients
JPWO2009028573A1 (ja) 血液凝固障害におけるリバビリンの利用
Ho et al. Ribozyme Gene Therapy Targeting Stem Cells for Human Immunodeficiency Virus Infection
Haller et al. Host defense mechanisms in genetic resistance to viral infections